Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 17 | 2022 | 670 | 1.300 |
Why?
|
| Neuropsychological Tests | 14 | 2022 | 1196 | 0.600 |
Why?
|
| Cognition Disorders | 8 | 2018 | 985 | 0.530 |
Why?
|
| Glucosylceramidase | 4 | 2022 | 15 | 0.500 |
Why?
|
| Subthalamic Nucleus | 2 | 2022 | 19 | 0.400 |
Why?
|
| Gait Disorders, Neurologic | 3 | 2020 | 133 | 0.400 |
Why?
|
| Deep Brain Stimulation | 2 | 2022 | 36 | 0.380 |
Why?
|
| Tourette Syndrome | 1 | 2009 | 11 | 0.320 |
Why?
|
| Accidental Falls | 2 | 2020 | 110 | 0.290 |
Why?
|
| Huntington Disease | 2 | 2020 | 48 | 0.240 |
Why?
|
| Cognition | 4 | 2022 | 1339 | 0.230 |
Why?
|
| Dementia | 4 | 2016 | 560 | 0.230 |
Why?
|
| Quality of Life | 1 | 2009 | 629 | 0.230 |
Why?
|
| Male | 22 | 2022 | 14772 | 0.220 |
Why?
|
| Middle Aged | 18 | 2022 | 8923 | 0.220 |
Why?
|
| Female | 22 | 2022 | 15213 | 0.220 |
Why?
|
| Executive Function | 4 | 2018 | 111 | 0.220 |
Why?
|
| Mutation | 4 | 2022 | 348 | 0.220 |
Why?
|
| Phonation | 1 | 2003 | 5 | 0.210 |
Why?
|
| Speech Disorders | 1 | 2003 | 10 | 0.210 |
Why?
|
| Aged | 18 | 2022 | 8997 | 0.210 |
Why?
|
| Electric Stimulation | 1 | 2003 | 51 | 0.210 |
Why?
|
| Speech | 1 | 2003 | 23 | 0.210 |
Why?
|
| Respiration | 1 | 2003 | 35 | 0.210 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2012 | 310 | 0.200 |
Why?
|
| Severity of Illness Index | 7 | 2017 | 879 | 0.200 |
Why?
|
| Heterozygote | 1 | 2022 | 100 | 0.180 |
Why?
|
| Cognitive Dysfunction | 4 | 2016 | 1061 | 0.180 |
Why?
|
| Hallucinations | 2 | 2014 | 42 | 0.170 |
Why?
|
| Humans | 23 | 2022 | 27074 | 0.170 |
Why?
|
| Movement Disorders | 2 | 2013 | 66 | 0.160 |
Why?
|
| Disease Progression | 3 | 2016 | 673 | 0.140 |
Why?
|
| Ataxia | 1 | 2018 | 76 | 0.140 |
Why?
|
| Tremor | 1 | 2018 | 104 | 0.140 |
Why?
|
| Corpus Callosum | 1 | 2017 | 12 | 0.140 |
Why?
|
| Fragile X Syndrome | 1 | 2018 | 188 | 0.120 |
Why?
|
| Postural Balance | 1 | 2016 | 117 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 1112 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 278 | 0.110 |
Why?
|
| Memory Disorders | 2 | 2014 | 159 | 0.110 |
Why?
|
| Psychotherapy, Psychodynamic | 1 | 2013 | 1 | 0.110 |
Why?
|
| Psychotherapy, Brief | 1 | 2013 | 2 | 0.110 |
Why?
|
| Nerve Net | 1 | 2014 | 40 | 0.110 |
Why?
|
| Somatoform Disorders | 1 | 2013 | 15 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2014 | 121 | 0.110 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 155 | 0.100 |
Why?
|
| Psychometrics | 1 | 2013 | 220 | 0.100 |
Why?
|
| Entorhinal Cortex | 1 | 2012 | 37 | 0.100 |
Why?
|
| Sleep Wake Disorders | 1 | 2013 | 123 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2020 | 587 | 0.090 |
Why?
|
| Atrophy | 3 | 2017 | 91 | 0.080 |
Why?
|
| Sleep | 1 | 2013 | 328 | 0.080 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2009 | 17 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 125 | 0.080 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2009 | 34 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2016 | 420 | 0.080 |
Why?
|
| Attention | 3 | 2014 | 124 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 4777 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 891 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2009 | 641 | 0.070 |
Why?
|
| Psychophysiologic Disorders | 1 | 2005 | 6 | 0.060 |
Why?
|
| Adolescent | 2 | 2009 | 2172 | 0.060 |
Why?
|
| Psychotherapy | 1 | 2005 | 39 | 0.060 |
Why?
|
| Adult | 5 | 2015 | 7831 | 0.060 |
Why?
|
| Child | 1 | 2009 | 1295 | 0.060 |
Why?
|
| Gait | 2 | 2020 | 412 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2020 | 3538 | 0.050 |
Why?
|
| Speech Articulation Tests | 1 | 2003 | 3 | 0.050 |
Why?
|
| Acoustics | 1 | 2003 | 19 | 0.050 |
Why?
|
| Task Performance and Analysis | 1 | 2003 | 47 | 0.050 |
Why?
|
| Mental Status Schedule | 2 | 2015 | 90 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 482 | 0.050 |
Why?
|
| Memory | 2 | 2013 | 297 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2022 | 347 | 0.040 |
Why?
|
| Walk Test | 1 | 2020 | 10 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2015 | 1890 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2020 | 205 | 0.040 |
Why?
|
| Walking Speed | 1 | 2018 | 41 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 60 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 164 | 0.030 |
Why?
|
| Depression | 2 | 2012 | 444 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 83 | 0.030 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 1 | 2015 | 5 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 708 | 0.030 |
Why?
|
| Space Perception | 1 | 2014 | 22 | 0.030 |
Why?
|
| Probability | 1 | 2014 | 88 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 346 | 0.030 |
Why?
|
| Language | 1 | 2014 | 63 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 64 | 0.030 |
Why?
|
| Sleep Stages | 1 | 2013 | 23 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1368 | 0.020 |
Why?
|
| Amnesia | 1 | 2012 | 24 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 95 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 260 | 0.020 |
Why?
|
| Checklist | 1 | 2011 | 33 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 139 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 302 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 474 | 0.020 |
Why?
|
| Hippocampus | 1 | 2012 | 273 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 676 | 0.020 |
Why?
|
| United States | 1 | 2015 | 2035 | 0.020 |
Why?
|
| Mass Screening | 1 | 2010 | 167 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2010 | 264 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 595 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 2005 | 38 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2005 | 102 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 97 | 0.020 |
Why?
|
| Anxiety | 1 | 2005 | 156 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 1433 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 1792 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 3485 | 0.010 |
Why?
|